Lab Information

Marina Klein (MD/MSc)

Senior Scientist
Centre for Outcomes Research and Evaluation
Department of Medicine (McGill)

Research Profile

 Fundamental: 0%
 Clinical: 20%
 Epidemiology: 80%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.


HIV • Hepatitis C • clinical trials • epidemiology • antiretrovirals • prospective cohort

Research Interests

My research focuses on the treatment of patients with HIV and chronic hepatitis. As a prominent researcher in clinical and epidemiologic aspects of HIV and Hepatitis C co-infection, I lead one the largest multicenter cohorts focused on HIV/HCV co-infection in the world, recruiting more than one thousand HIV/HCV co-infected patients across Canada. The primary objectives of the CIHR funded cohort are to study the interactions between these two chronic viruses and their natural history in the era of combination antiretroviral therapy (cART) and to evaluate therapeutic strategies aimed at improving health outcomes in co-infected persons. We are also focused on understanding the roles of co-morbidities in the natural history of HIV/HCV co-infection. In addition, I am involved in a number of observational epidemiologic research collaborations (NA-ACCORD and CANOC) that focus on understanding long term clinical and treatment outcomes in HIV infection. My other research interests include antiretroviral pharmacoepidemiology and HIV infection in women.

Team Members

Name Position

Latest Publications

  1. Benmassaoud, A., Macias, J., Delamarre, A., Corma-Gomez, A., Guaraldi, G., Milic, J., Rockstroh, J. K., Van Bremen, K., Tsochatzis, E., Mulay, A., Price, J., Garvey, L. J., Lemoine, M., Kablawi, D., Lebouche, B., Klein, M. B., Ballesteros, L. R., Boesecke, C., Schepis, F., Bhagani, S., Cooke, G., Berzigotti, A., Hirose, K., Pineda, J. A., Ramanakumar, A. V., De-Ledinghen, V., Saeed, S. & Sebastiani, G. (2023). Prognostic value of non-invasive scores based on liver stiffness measurement, spleen diameter and platelets in HIV-infected patients. Liver international : official journal of the International Association for the Study of the Liver.
  2. Lanièce Delaunay, C., Klein, M. B., Godin, A., Cox, J., Kronfli, N., Lebouché, B., Doyle, C. & Maheu-Giroux, M. (2023). Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study. The International journal on drug policy, vol. 116, p. 104026.
  3. Passos-Castilho, A. M., Murphy, D. G., Blouin, K., Benedetti, A., Panagiotoglou, D., Bruneau, J., Klein, M. B., Kwong, J. C., Sander, B., Janjua, N. Z. & Greenaway, C. (2023). A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada. Journal of viral hepatitis.
  4. Hlavay, B. A., Zhuo, R., Ogando, N., Charlton, C., Stapleton, J. T., Klein, M. B. & Power, C. (2023). Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, vol. 162, p. 105445.
  5. Isfordink, C. J., Boyd, A., Sacks-Davis, R., van Santen, D. K., Smit, C., Martinello, M., Stoove, M., Berenguer, J., Wittkop, L., Klein, M. B., Rauch, A., Salmon, D., Lacombe, K., Stewart, A., Schinkel, J., Doyle, J. S., Hellard, M., van der Valk, M., Matthews, G. V. & InCHEHC study group (2023). Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study. The Lancet. Public health, vol. 8, p. e294-e304.
  6. Klein, M. B. (2023). Living longer with HIV: gains for some but not for all. The lancet. HIV, vol. 10, p. e275-e276.
  7. Young, J., Wang, S., Lanièce Delaunay, C., Cooper, C. L., Cox, J., Gill, M. J., Hull, M., Walmsley, S., Wong, A., Klein, M. B. & Canadian Coinfection Cohort Investigators (2023). The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination. The International journal on drug policy, vol. 114, p. 103981.
  8. Zhabokritsky, A., Clarke, R., Rosenes, R., Smith, G., Loutfy, M., Andany, N., Falutz, J., Klein, M., Harris, M., Guillemi, S., Tan, D. H. S., Arbess, G. & Walmsley, S. (2023). Correlates of Healthy Aging in Geriatric HIV (CHANGE HIV)-CTN 314. Viruses, vol. 15.
  9. Lam, C., Landry, S., Moussa, G., Sakr, D., Varinot, G., Mousseau, K., Martel, D., Frenette, A. J., Ambaraghassi, G., Rouleau, D., Cantarovich, M., Klein, M. B., Sheehan, N. L. & Lemire, B. (2023). Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review. Transplantation direct, vol. 9, p. e1441.
  10. Sangaré, M. N., Baril, J.-G., de Pokomandy, A., Klein, M., Thomas, R., Tremblay, C., Pexos, C., Durand, M., Chawla, S., Laporte, L. & Trottier, H. (2023). CD4/CD8 ratio outcome according to the class of the third active drug in antiretroviral therapy (ART) regimens: results from the Quebec Human Immunodeficiency Virus (HIV) Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
More on PubMed 

See also

Card image

See profile
Card image

See profile
Card image

See profile
Card image
De Pokomandy

See profile
Card image

See profile
Card image

See profile